Michaela Hackett finished the 6K course in 20:38.4 less than one-second behind Vilanova’s Nicole Hutchinson (20:37.8) to finish in 91st. Twin sister Allie Hackett finished 107th, clocking a time of 20:45.9 that was a half second behind Penn State’s Kathryn Munks (20:45.4).”Allie and Michaela had solid races today and gave it everything they had,” said distance coach Jarvis Jelen. “They also learned a lot from their first National Championship race. I’m confident that they will take what they’ve learned and continue to improve during the upcoming track season. We are all very proud of Allie and Michaela for how they competed during this race, this season, and during their careers up to this point at ACU. I have been extremely blessed to coach them for the last couple of years. They have made a long-lasting positive impact on our program and will continue to do so in the remainder of their senior season.”Leaders in the race! Watch the finish live on FloTrack: https://t.co/udVgBfdUVq pic.twitter.com/TSIUUicYLF— FloTrack (@FloTrack) November 18, 2017 New Mexico grabbed the team title for the second time in three years with 90 team points and University of San Francisco earned runner-up honors with 105 points. A trio of Pac-12 schools rounded out the top-five: Colorado (139) placed third while Stanford (165) and Oregon (203) were fourth and fifth, respectively.The Northern Arizona men paced to a first-place team finish with 74 points followed by Portland (127). BYU (165), Stanford (221) and South Central Region foe Arkansas (259).Courtesy of Abilene Christian Athletics New Mexico’s Ednah Kurgat paced through the course in 19:19.5 to grab the top spot on the podium. Washington’s Amy-Eloise and San Francisco’s Charlotte Taylor took second and third, respectively, with times of 19:27.0 and 19:28.6. ResultsLOUISVILLE, Ky. – Michaela and Alexandria Hackett finished their redshirt senior cross country season at the 2017 NCAA National Championships Saturday at E.P. “Tom” Sawyer Park.
A discovery of a rare mutation that affects cholesterol has ignited hopes of a prescription that can help prevent heart attacks. In the meantime, an announcement by Roche could pose more questions about controversial diabetes medicines. Also a federal report warns Americans of using some Internet pharmacies.The New York Times: Rare Mutation Ignites Race For Cholesterol DrugShe was a 32-year-old aerobics instructor from a Dallas suburb — healthy, college educated, with two young children. Nothing out of the ordinary, except one thing. Her cholesterol was astoundingly low. … The discovery of the mutation and of the two women with their dazzlingly low LDL levels has set off one of the greatest medical chases ever. It is a fevered race among three pharmaceutical companies, Amgen, Pfizer and Sanofi, to test and win approval for a drug that mimics the effects of the mutation, drives LDL levels to new lows and prevents heart attacks. All three companies have drugs in clinical trials and report that their results, so far, are exciting (Kolata, 7/9).The New York Times: Roche Abandons New Diabetes DrugRoche, the Swiss pharmaceutical giant, has discontinued development of a potentially important diabetes drug, a move that could raise new safety questions about the entire category of drugs, which includes the controversial diabetes medicine Avandia (Pollack, 7/9).Stateline: Rogue Internet Pharmacies Dangerous Says Federal ReportIn their search for cheaper prescription drugs, Americans are increasingly turning to Internet pharmacies, many of which federal investigators say skirt U.S. and state regulations and sell misbranded, adulterated and counterfeit drugs. These transactions — often without a legitimate prescription — put consumers at risk, the U.S. Government Accountability Office said in a new report released Monday (Ollove, 7/9). Pharmaceutical Companies Race For New Cholesterol Drugs This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.